Defining key signaling nodes and therapeutic biomarkers in NF1-mutant cancers.
about
Glucose transport: meeting the metabolic demands of cancer, and applications in glioblastoma treatmentCotargeting MNK and MEK kinases induces the regression of NF1-mutant cancersTherapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosisMalignant Peripheral Nerve Sheath Tumors State of the Science: Leveraging Clinical and Biological Insights into Effective Therapies.The Conundrum of Genetic "Drivers" in Benign Conditions.Clinical and Molecular Characteristics of NF1-Mutant Lung Cancer.CK2 blockade causes MPNST cell apoptosis and promotes degradation of β-cateninReview of low-grade gliomas in children--evolving molecular era and therapeutic insights.Sexual dimorphism in glioma glycolysis underlies sex differences in survivalTargeting group I p21-activated kinases to control malignant peripheral nerve sheath tumor growth and metastasis.Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.A Collaborative Model for Accelerating the Discovery and Translation of Cancer Therapies.Imaging Cancer Metabolism.Differential Response of Glioma Stem Cells to Arsenic Trioxide Therapy Is Regulated by MNK1 and mRNA Translation.Biology and Management of Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma, and Malignant Peripheral Nerve Sheath Tumors: State of the Art and Perspectives.mTOR and HDAC Inhibitors Converge on the TXNIP/Thioredoxin Pathway to Cause Catastrophic Oxidative Stress and Regression of RAS-Driven Tumors.The path forward: 2015 International Children's Tumor Foundation conference on neurofibromatosis type 1, type 2, and schwannomatosis.Current treatment options for malignant peripheral nerve sheath tumors.
P2860
Q28078559-6F1F98B8-2E25-4F13-B88C-AF21D538C8E5Q28829666-5ED97B3D-C1C2-449E-B516-A60B301E8337Q30357776-B6B02957-6166-4359-9145-08049E346958Q33737662-CDEFA9B9-F61A-4629-B7C5-1ADD2CE31FB6Q37245787-1A9B478B-A59D-4651-836B-9654C3401325Q37455251-C28AFA8D-5D15-4FA2-BD71-09F35496933FQ37619722-2745C749-E16B-437A-97CB-BDD74F0DD2FFQ38365733-836FC87B-F076-42C4-B4C4-C2352980336CQ38645948-B2822ECB-E64F-437A-BB9F-16AB3E100F13Q38769437-7988951C-C6D6-4DED-BB14-9164744A060BQ38819110-548E6469-9699-4C68-B7C7-E3615CFF30ACQ45955739-6BBFB096-4E23-4ACC-B264-0B5BF0B1F46FQ47117264-54469763-0FCB-486C-AC5E-28C2A0CAFEF7Q47435333-F2C2ED1C-A40A-4994-A968-26AC82E46B6FQ47793357-85003759-18E0-4CD8-831C-16F9EB77102FQ52753134-DEA40655-06EF-4F79-8E35-DA3A76167D44Q53338183-D45C1BB7-208F-4811-AAFD-C983DCBB9490Q53581736-56F68F24-7A8C-453F-B7C6-6D8B6B77BCA3
P2860
Defining key signaling nodes and therapeutic biomarkers in NF1-mutant cancers.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Defining key signaling nodes and therapeutic biomarkers in NF1-mutant cancers.
@ast
Defining key signaling nodes and therapeutic biomarkers in NF1-mutant cancers.
@en
type
label
Defining key signaling nodes and therapeutic biomarkers in NF1-mutant cancers.
@ast
Defining key signaling nodes and therapeutic biomarkers in NF1-mutant cancers.
@en
prefLabel
Defining key signaling nodes and therapeutic biomarkers in NF1-mutant cancers.
@ast
Defining key signaling nodes and therapeutic biomarkers in NF1-mutant cancers.
@en
P2093
P2860
P1433
P1476
Defining key signaling nodes and therapeutic biomarkers in NF1-mutant cancers.
@en
P2093
Clare F Malone
Jody A Fromm
Karen Cichowski
Ophélia Maertens
Rachel Ingraham
Thomas DeRaedt
P2860
P304
P356
10.1158/2159-8290.CD-14-0159
P577
2014-06-09T00:00:00Z